Vistagen (NASDAQ: VTGN) reported preliminary positive data from the open-label extension portion of its PALISADE-3 Phase 3 study of fasedienol ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE